Fox, Elizabeth <br/><br/>
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 2010 
 - 5174-81 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.30.9674  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adolescent<br/>Antineoplastic Agents--administration & dosage<br/>Area Under Curve<br/>Child<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Neoplasms--drug therapy<br/>Quinazolines--administration & dosage<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors